Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
© 2012 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
M, male; F, female;TR, total resection; GTR, grossly total resection; STR, subtotal resection; C/RT, chemotherapy/radiotherapy; ND, not described.
aThe table is a modified version of Table 1 from the work of Adamek et al.10; bMonths from the date of operation to last follow-up visit or recurrence; cAfter gadolinium injection; dOn the basis of criteria set forth by the World Health Organization (WHO),1 the neoplasm we described with marked cellularity, abundant mitoses, perivascular pseudorosettes, vascular proliferation, and necrosis would be classified as an anaplastic ependymoma (WHO Grade III); eThe patient was alive 8 months after surgery with recent evidence of enhancement at the tumor resection site. It was not clear at that time whether the enhancement represented tumor recurrence or postoperative/radiation sequelae; fThe patient died suddenly with signs of respiratory insufficiency; gThey report the suprasellar giant cell ependymoma occurring in a 34-year-old female 7 years after an initial diagnosis of a medullary ependymoma with rare atypical giant cells. Incomplete resection and, possibly, incomplete radiotherapy may have contributed to tumoral seeding; hThe patient had a recurrence of severe Clostridium difficile colitis, complicated by renal failure requiring dialysis. This was further complicated by congestive heart failure and pneumonia, and the patient died 6 weeks after the surgery; iThey report tanycytic ependymoma with many pleomorphic giant cells and suggest that it could be termed "giant cell tanycytic ependymoma."
H, high; M, moderate; ND, not described.
aCase No., same as the Table 1; bThe cytologic feature is not described at the literature.
M, male; F, female;TR, total resection; GTR, grossly total resection; STR, subtotal resection; C/RT, chemotherapy/radiotherapy; ND, not described. aThe table is a modified version of Table 1 from the work of Adamek et al.
H, high; M, moderate; ND, not described. aCase No., same as the